CN Mobile Logo

Search form


Latest Issue

ONCOLOGY Vol 31 No 2

This article reviews newly approved drugs for hematologic malignancies: their indications, mechanisms of action, accompanying pivotal trial data, pertinent toxicities, use in special populations, and appropriate clinical context.

Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is rapidly changing due to a variety of conceptually important clinical trials and emerging new options.

A 60-year-old man with a history of coronary artery disease and JAK2 V617F–positive polycythemia vera presented to our bone marrow transplantation clinic with progressive fatigue, splenomegaly, and cytopenias.

This article focuses on the new agents and indications that emerged in 2016 for solid tumor treatment. We review the drug indications, mechanisms of action, pivotal trial data, pertinent toxicities, use in special populations, and the appropriate clinical contexts for treatment planning.

We know that breast cancer represents a spectrum of diseases, with variation in prognosis, and that RT can range from highly complex treatments to the breast and regional lymph nodes, to complete avoidance of radiation.

To paraphrase a deep philosophical question: if an important, long-awaited phase III prospective randomized trial from Europe is published and no one pays attention, does it make a sound?

A better delineation of the relationships between lung cancer, COPD, and emphysema may lead to significant improvements in the effectiveness of lung cancer screening programs, and to reductions in the morbidity and mortality associated with these deadly diseases.

In this interview we discuss how the ACA, which was passed in 2010, changed the way oncologists treat their patients, and how a repeal of the law would affect patients’ access to care.


By clicking Accept, you agree to become a member of the UBM Medica Community.